- Home
- ADPT
as 12-18-2024 12:30pm EST
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 929.8M | IPO Year: | 2019 |
| Target Price: | $6.50 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.28 - $7.07 | Next Earning Date: | 02-12-2025 |
| Revenue: | $177,282,000 | Revenue Growth: | -1.34% |
| Revenue Growth (this year): | 6.48% | Revenue Growth (next year): | 18.84% |
Stock Insider Trading Activity of Adaptive Biotechnologies Corporation (ADPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PISKEL KYLE | ADPT | Chief Financial Officer | Nov 18 '24 | Sell | $4.98 | 248 | $1,235.04 | 154,330 |
Latest Adaptive Biotechnologies Corporation News
ADPT Breaking Stock News: Dive into ADPT Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Are Medical Stocks Lagging BellRing Brands (BRBR) This Year?
Medical Device Network
9 days ago
Adaptive unveils data of MRD assessment test in blood cancer treatment
GlobeNewswire
11 days ago
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
Clinical Trials Arena
13 days ago
Adaptive Research and WRO to expand cancer trial access in San Francisco Bay Area
GlobeNewswire
15 days ago
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
Zacks
19 days ago
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
Clinical Trials Arena
23 days ago
Novotech report notes shift to adaptive designs in clinical trials
Zacks
a month ago
Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know
Compare ADPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADPT Adaptive Biotechnologies Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.